The company’s bispecific antibody platform is PACbody™ , a proprietary approach for constructing bispecific antibodies without using protein engineering so that the antibody molecules maintain native structures with superb CMC characteristics.

A second technology platform the company is developing is ATACC™ , a proprietary technology for targeting solid tumors using immuno-oncology molecules with minimal risk of cytokine release syndrome (CRS).